ResearcherGerman Cancer Research CenterActive in the last 2 years

Markus W. Loeffler

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2513-1317; OpenAlex author ID A5112582631. Sources: OpenAlex.

Their work

Papers: 3 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 8

Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: none · 2024: 2 papers

Papers 3

Quantitative Metabolomics and Lipoprotein Analysis of PDAC Patients Suggests Serum Marker Categories for Pancreatic Function, Pancreatectomy, Cancer Metabolism… Co-author DOI 10.1021/acs.jproteome.3c00611 ↗
Long-term recurrence-free survival following pancreatic surgery with HIPEC treatment for locally advanced pancreatic adenocarcinoma. Co-author DOI 10.1136/bcr-2023-258626 ↗
A Prospective, Phase I/II, Open-Label Pilot Trial to Assess the Safety of Hyperthermic Intraperitoneal Chemotherapy After Oncological Resection of Pancreatic A… Last author DOI 10.1245/s10434-021-10187-8 ↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Can Yurttas · 2 shared papers, 2021–2024 · strength 0.41
- Paper Long-term recurrence-free survival following pancreatic surgery with HIPEC treatment for locally advanced pancreatic ad… DOI 10.1136/bcr-2023-258626 ↗
- Paper A Prospective, Phase I/II, Open-Label Pilot Trial to Assess the Safety of Hyperthermic Intraperitoneal Chemotherapy Aft… DOI 10.1245/s10434-021-10187-8 ↗
André L. Mihaljević · 1 shared paper, 2024 · strength 0.28
- Paper Long-term recurrence-free survival following pancreatic surgery with HIPEC treatment for locally advanced pancreatic ad… DOI 10.1136/bcr-2023-258626 ↗
Valerie Zimmermann · 1 shared paper, 2024 · strength 0.28
- Paper Long-term recurrence-free survival following pancreatic surgery with HIPEC treatment for locally advanced pancreatic ad… DOI 10.1136/bcr-2023-258626 ↗
Gyuntae Bae · 1 shared paper, 2024 · strength 0.21
- Paper Quantitative Metabolomics and Lipoprotein Analysis of PDAC Patients Suggests Serum Marker Categories for Pancreatic Fun… DOI 10.1021/acs.jproteome.3c00611 ↗
Christoph Trautwein · 1 shared paper, 2024 · strength 0.21
- Paper Quantitative Metabolomics and Lipoprotein Analysis of PDAC Patients Suggests Serum Marker Categories for Pancreatic Fun… DOI 10.1021/acs.jproteome.3c00611 ↗
Patrick Michl · 1 shared paper, 2024 · strength 0.21
- Paper Quantitative Metabolomics and Lipoprotein Analysis of PDAC Patients Suggests Serum Marker Categories for Pancreatic Fun… DOI 10.1021/acs.jproteome.3c00611 ↗
Stefan Beckert · 1 shared paper, 2021 · strength 0.13
- Paper A Prospective, Phase I/II, Open-Label Pilot Trial to Assess the Safety of Hyperthermic Intraperitoneal Chemotherapy Aft… DOI 10.1245/s10434-021-10187-8 ↗
Ingmar Königsrainer · 1 shared paper, 2021 · strength 0.13
- Paper A Prospective, Phase I/II, Open-Label Pilot Trial to Assess the Safety of Hyperthermic Intraperitoneal Chemotherapy Aft… DOI 10.1245/s10434-021-10187-8 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.